The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

Disease insight reports

Parkinson’s Disease: The Impact of Covid-19

Data published by Wilmington Healthcare, Parkinson’s Concierge and Parkinson’s Academy highlight the impact of the COVID-19 Pandemic and NHS contact to people with Parkinson’s.

Interested? Get in touch

The COVID-19 Pandemic has made a dramatic difference to the way in which people with Parkinson’s (PwP) see their Parkinson’s team. A new summary of data by healthcare intelligence provider Wilmington Healthcare, Parkinson’s Concierge and the transformative educator Parkinson’s Academy has highlighted the huge impact COVID -19 has had on people with Parkinson’s and Parkinson’s services.

The data reveals:

  • Telephone consultations increased by 239% in response to the dramatic drop in face to face out-patient appointments
  • Elective admissions were reduced by 57%
  • Emergency admissions reduced by 18.6%

Clinical teams have responded well in the pandemic by significantly increasing their contact with patients over the phone but both elective admissions and emergency admissions were reduced.

In England emergency admissions in PwP have continually increased over the prior three years so what has happened to these in the pandemic? Are these hidden emergencies?

According to HES data for the 2019/20 year there were 77,318 emergency hospital admissions for Parkinson’s which cost the NHS £301 million. The average cost of an emergency admission was £3,889 and the average length of stay was 10.3 days. Emergency admissions were for bladder infections (£26 million), pneumonia (£19m) falls (£18m) and sepsis (£15m). Did PwP avoid seeking help?

Download our infographic detailing the impact of Covid-19 on Parkinson’s Disease.

Sue Thomas, CEO of Wilmington Healthcare Consulting, said:

“Our latest report shows that the problems that have occurred in the pandemic and the way that NHS staff have risen to the challenge of providing innovative virtual ways to see their patients but the real concern is the drop in both planned and emergency as this might have had unintended and life changing consequences. For PwP who require complex therapy like carbidopa/ levodopa or deep brain stimulation there may only be a short window during which they can be effective. Does this mean some individuals may have lost their opportunity to have therapy in the pandemic? PwP frequently experience complications like chest or urine infections which need to be treated promptly – have they avoided seeking crisis support to their detriment? Will this lack of intervention rebound and affect them in the longer term?”

Charlotte Allen & Russ Bradford, Co-Founders of Parkinson’s Concierge said
“We feel that the sharp decline in A&E attendance from people with Parkinson’s since the COVID-19 epidemic and subsequent lockdown restrictions, is due from a number of factors. One reason is the fact that many people with Parkinson’s are fearful, scared and anxious of the increased risk of exposure to infection, alongside their existing Parkinson’s symptoms. There was also great uncertainty what category people with Parkinson’s fell into at the start of the pandemic “are we vulnerable or should we be classed as extremely vulnerable?” they said.

Daiga Hesters, Interim Head of the Parkinson’s Academy said:

“As the report shows, the pandemic has required innovation to change how Parkinson’s teams support their patients. Parkinson’s Academy has been with these teams every step of the way, providing an opportunity for learning through our series of webinars, so that health professionals have felt supported and ready for the challenges ahead. More webinars are planned for later in the year, supporting services to further adapt and learn from positive practice around the country, and to deliver the more complex therapies in novel ways”.